IDEAYA Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net loss | $(113,698) | $(274,477) | $(112,961) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation and amortization | 2,700 | 2,387 | 2,476 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | (9,976) | (23,233) | (11,553) |
| Stock-based compensation | 46,115 | 34,746 | 18,489 |
| Amortization of right of use assets | 1,893 | 1,447 | 1,532 |
| Changes in assets and liabilities | |||
| Accounts receivable | — | — | 193 |
| Prepaid expenses and other assets | (7,840) | (6,159) | (2,045) |
| Accounts payable | 2,697 | 8,280 | 2,635 |
| Accrued and other liabilities | 10,427 | 10,794 | 1,635 |
| Contract assets and liabilities | (5,973) | — | (13,753) |
| Lease liabilities | 2,557 | (1,369) | (1,872) |
| Net cash used in operating activities | (71,098) | (247,584) | (115,224) |
| Cash flows from investing activities | |||
| Purchases of property and equipment, net | (2,368) | (3,857) | (2,368) |
| Purchases of marketable securities | (607,889) | (1,191,309) | (595,980) |
| Maturities of marketable securities | 680,233 | 692,607 | 439,892 |
| Net cash provided by (used in) investing activities | 69,976 | (502,559) | (158,456) |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock in public offering, net of issuance costs | — | 274,350 | 281,165 |
| Proceeds from issuances of pre-funded warrants | — | 9,400 | 42,182 |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | 24,855 | 379,879 | 28,598 |
| Proceeds from exercise of common stock options | 3,431 | 12,483 | 9,559 |
| Proceeds from ESPP purchases | 1,493 | 1,439 | 1,213 |
| Net cash provided by financing activities | 29,779 | 677,551 | 362,717 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,657 | (72,592) | 89,037 |
| Cash, cash equivalents and restricted cash | |||
| Cash, cash equivalents and restricted cash, at beginning of period | 85,183 | 157,775 | 68,738 |
| Cash, cash equivalents and restricted cash, at end of period | $113,840 | $85,183 | $157,775 |
| Reconciliation of cash, cash equivalents and restricted cash | |||
| Cash and cash equivalents | $112,825 | $84,378 | $157,018 |
| Restricted cash | 1,015 | 805 | 757 |
| Cash, cash equivalents and restricted cash | $113,840 | $85,183 | $157,775 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $— | $25 | $69 |
| Supplemental non-cash investing and financing activities: | |||
| Right-of-use asset obtained in exchange for a new operating lease liability | $6,186 | $17,976 | $1,294 |
| Purchases of property and equipment in accounts payable and accrued liabilities | 1,062 | 1,479 | 147 |
| Unpaid offering costs | — | — | 43 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.